Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 8/20 | 0.51 |
| ▸ | CKS1B | P61024 | 2/20 | 0.48 |
| ▸ | SKP1 | P63208 | 2/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.44 |
| ▸ | KRAS | P01116 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533932 | 0.94 | SMO (0.43) | SMOCKS1BSKP1SKP2 | |
| SCHEMBL12841340 | 0.92 | AOC3 (0.44) | SMOCKS1BSKP1SKP2 | |
| SCHEMBL9932565 | 0.91 | SMO (0.41) | SMOCKS1BSKP1SKP2 | |
| SCHEMBL9968433 | 0.91 | SMO (0.52) | SMOCKS1BSKP1SKP2OPRM1 | |
| SCHEMBL9931939 | 0.89 | SMO (0.62) | SMOCKS1BSKP1SKP2 | |
| SCHEMBL9932426 | 0.89 | FASN (0.49) | SMOCKS1BSKP1SKP2BRD4 | |
| SCHEMBL9968523 | 0.88 | CKS1B (0.52) | SMOCKS1BSKP1SKP2OPRM1 | |
| SCHEMBL9968432 | 0.85 | SMO (0.56) | SMOOPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL9931814 | 0.84 | SMO (0.49) | SMO | |
| SCHEMBL9931741 | 0.84 | SMO (0.56) | SMOCKS1BSKP1SKP2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027249-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157471-A1 | BENZIMIDAZOLE DERIVATIVES | SMO, RB1, GLI1 | SMO 1/4885CKS1B 187/4885SKP1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.